

AMENDMENTS

In the Specification:

Please make the following changes in the specification:

Paragraph 71:

On page 39, line 1: Please replace "Table 30" with "Table 28"

On page 39, line 8: Please replace "Table 32" with "Table 30"

Paragraph 174:

On page 109, line 3, after "Suc-Ala-Ala-Pro-Val-pNA," please insert --(SEQ ID NO: 33)--

In the Claims:

Please amend claims 1-3 and 24 as follows:

1. (Once Amended) A fusion protein comprising a first protease inhibitor comprising alpha 1-antitrypsin or a functionally active portion thereof, and a second protease inhibitor or a functionally active portion thereof, wherein said fusion protein has protease inhibitor activity.

2. (Once Amended) A fusion protein comprising alpha 1-antitrypsin or a functionally active portion thereof, and secretory leukocyte protease inhibitor or a functionally active portion thereof, wherein said fusion protein has protease inhibitor activity.

3. (Once Amended) A fusion protein comprising alpha 1-antitrypsin or a functionally active portion thereof, and a tissue inhibitor of metalloproteases or a functionally active portion thereof, wherein said fusion protein has protease inhibitor activity.

a¹

a² 24. (Once Amended) A fusion protein comprising

a) a polypeptide comprising amino acids from about 1 to about 394 of alpha 1-antitrypsin; and

b) a polypeptide comprising amino acids from about 1 to 127 of tissue inhibitor of metalloproteases-1, wherein the alpha 1-antitrypsin polypeptide is covalently linked to the tissue inhibitor of metalloproteases-1 polypeptide through a disulfide bond between amino acid 127 of the tissue inhibitor of metalloproteases-1 polypeptide and a free cysteine residue of the alpha 1-antitrypsin polypeptide,

wherein said fusion protein has protease inhibitor activity.
